Follow-up survey following the completion of 'A open-label, randomized controlled study of adjuvant therapy with TAP-144-SR (3M) in premenopausal breast cancer patients'

Not Applicable

• Conditions: Postsurgical of premenopausal breast cancer

• Registration Number: JPRN-UMIN000006050
• Lead Sponsor: Public Health Research Foundation. Comprehensive Support Project for Oncology Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-10-01
• Study Completion: 2020-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 222

Inclusion Criteria

Not provided

Exclusion Criteria

1) The subject has received preoperative hormone therapy prior to breast cancer surgery. 2) The subject has received postoperative adjuvant hormone therapy prior to the study enrollment. 3) The subject has received bilateral oophorectomy and irradiation to bilateral ovaries. 4) The subject has inflammatory breast cancer or bilateral breast cancer. 5) The subject has double cancer or has a history of carcinoma in other organs. 6) The subject is pregnant or breast-feeding, and of child-bearing potential. 7) The subject has past history of hypersensitivity to the study drug component or synthetic LH-RH, LH-RH derivative, and TAM or TAM analogue (antiestrogen). 8) The subject has severe complications.

Study & Design

• Study Type: Observational
• Study Design: Not specified